Medical/Pharmaceuticals
Amaran Biotech Wins Asia-Pacific Biologics CDMO Excellence Award for "Best Fill-Finish"
50-Person Team Demonstrates Taiwan's Biotech Strength HSINCHU, Sept. 11, 2025 /PRNewswire/ -- Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), was awarded the "Best Fill-Finish" at the 2025 Asia-Pacific Biologics CDMO Excellence Awards held inSingapore...
2025-09-11 10:00
2206
Fosun International Recognized among Fortune's 2025 "Most Admired Chinese Companies" List
HONG KONG, Sept. 11, 2025 /PRNewswire/ -- On 9 September, Fortune China magazine released its 2025 list of "Most Admired Chinese Companies", in which Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) was included in the Industry Star List. This highligh...
2025-09-11 09:00
3037
XingImaging in partnership with SynuSight was awarded a grant from The Michael J. Fox Foundation to support development of the α-synuclein PET tracer 18F-FD4 for Parkinson's disease
NEW HAVEN, Conn., Sept. 11, 2025 /PRNewswire/ -- XingImaging in partnership with SynuSight Biotech has received funding of$3.84M from The Michael J. Fox Foundation to conduct studies on18F-FD4, a specific α-synuclein (α-syn)-targeted PET tracer. Based on prior investigator-initiated trials, the ...
2025-09-11 05:06
1081
TVM Capital Healthcare Announces First Closing of its USD 150 Million Southeast Asia Fund
SINGAPORE, Sept. 11, 2025 /PRNewswire/ -- TVM Capital Healthcare, a global private equity investor and operator specialized in healthcare growth capital across emerging markets, today announced the first closing of itsUSD 150 million TVM Healthcare Southeast Asia Fund ("SEA Fund"). The SEA Fund ...
2025-09-11 02:39
2396
Imaging Endpoints Announces Patent Application for AI Review Charter System
SCOTTSDALE, Ariz., Sept. 10, 2025 /PRNewswire/ -- Imaging Endpoints (IE), the global leader in Imaging CRO technologies and services for oncology trials, announced the filing of a provisional patent application for its revolutionary AI enhanced Imaging Review Charter (IRC) system. This innovative...
2025-09-10 21:00
1166
Optain Health Closes $26 Million Series A to Bring Oculomics to Primary Care and Beyond
Insight Partners leads; seven major U.S. health systems join. Funding accelerates the global rollout of Optain's advanced robotic retinal imaging, AI, and teleophthalmology platform. NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Optain Health, a healthcare technology company applying artificial intel...
2025-09-10 20:00
1996
New Public Perception Survey Highlights Fragmented Cancer Care Pathway in the Philippines; Optimism About Digital Innovations
* YouGov survey finds strong belief in value of early detection (76%) but low screening uptake (13%) * Confidence in coordinated care (34%) and in 'one-stop' care (36%) among the lowest inSoutheast Asia * Strongest regional demand for advanced technology in follow-up care and recurrence det...
2025-09-10 14:00
1452
New Public Perception Survey Highlights Fragmented Cancer Care Pathway in Thailand; Optimism About Digital Innovations
* YouGov survey finds strong belief in value of early detection (88%) but under half screened (40%) * 84% of respondents aware post-treatment care exists, 55% lack understanding of what it involves * Findings show confidence in "one-stop" cancer services and cautious optimism for digital in...
2025-09-10 11:39
2197
New Public Perception Survey Highlights Fragmented Cancer Care Pathway in Indonesia; Optimism About Digital Innovations
* YouGov survey finds belief in value of early detection (65%) but very low screening uptake (8%) * 76% of respondents aware post-treatment care exists, 58% lack understanding of what it involves * Confidence in coordinated care (39%) and in 'one-stop' care (31%) among lowest inSoutheast As...
2025-09-10 11:24
2245
Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis
MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation ...
2025-09-10 07:01
1583
Metabolon Partners with China Kadoorie Biobank to Advance Precision Health
The landmark multiomics study will examine how lifestyle, environmental,
socioeconomic, and genetic factors play a significant role in shaping common
diseases
MORRISVILLE, N.C., Sept. 9, 2025 /PRNewswire/ -- Metabolon
2025-09-09 21:00
1529
XtalPi AI Drug Discovery Collaboration Reaches Milestone as PharmaEngine's Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals
SHENZHEN, China, Sept. 9, 2025 /PRNewswire/ -- XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. (TWO:4162), has received regulatory clearances to initiate Phase 1 c...
2025-09-09 20:42
2703
Elevating Healthcare Innovation: ICP DAS-BMP Brings Advanced TPU Portfolio at Medtec China 2025
HSINCHU, Sept. 9, 2025 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), a Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), is pleased to announce its participation in Medtec China 2025, to be held fromSeptember 24 to 26 at the Shanghai World Expo Exhibit...
2025-09-09 09:45
2263
Sirtex Receives Expanded CE Mark Approval for SIR-Spheres® Y-90 Resin Microspheres
Broadened indication increases access to liver cancer treatment across Europe and CE-marked territories. WOBURN, Mass., Sept. 8, 2025 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of minimally invasive interventional oncology solutions, today announced that it has received an...
2025-09-08 21:00
1308
SpaceGut's Precision AI System for Gut Testing Achieves Up to 87% Improvement in Irritable Bowel Syndrome Management
KUALA LUMPUR, Malaysia, Sept. 8, 2025 /PRNewswire/ -- SpaceGut
2025-09-08 20:37
1940
FDA Accepts Letter of Intent to Qualify LSM by VCTE (FibroScan®) as First Non-Invasive Surrogate Endpoint in MASH Clinical Trials
This milestone opens a path for FibroScan® to ultimately replace liver biopsy
for patient enrollment and treatment response assessment in MASH drug
development
WESTBOROUGH, Mass., Sept. 8, 2025 /PRNewswire/ -- Echosens
2025-09-08 18:00
1272
Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
* Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company * KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA * Acquisition strengthens ...
2025-09-08 15:49
910
Gushengtang's H1 2025 Net Profit Climbs 41.6% Driven by Digital Health Adoption and International Expansion
GUANGZHOU, China, Sept. 8, 2025 /PRNewswire/ -- On August 29, Gushengtang (HKG:2273) announced its interim results for 2025, reporting strong operational and financial performance. The company posted revenue ofRMB 1.49 billion, representing a 9.5% year-on-year increase. Net profit grew 41.6% year...
2025-09-08 15:35
5214
Siriraj × MIT Hacking Medicine 2025 Now Open for Applications Across Southeast Asia: A Call for Innovation to Tackle Greatest Healthcare Challenges
BANGKOK, Sept. 8, 2025 /PRNewswire/ -- Siriraj Hospital and MIT Hacking Medicine have joined forces once again to host the second edition of their medical innovation hackathon, Siriraj × MIT Hacking Medicine 2025, taking place fromOctober 31 to November 2, 2025. Applications are now open for part...
2025-09-08 14:39
2377
Huadong Medicine Announces Positive Preliminary Results from a Phase Ⅰ study of HDM2005, a ROR1-Targeting ADC
HANGZHOU, China, Sept. 5, 2025 /PRNewswire/ -- Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine") today announced positive preliminary results from a Phase I study of HDM2005, an independently developed Class 1 innovative antibody–drug conjugate (ADC) targeting receptor ty...
2025-09-05 21:38
2735
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 310 media titles]
2026-02-23 08:00
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 289 media titles]
2026-02-23 10:09
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 280 media titles]
2026-02-17 19:12
Kung Fu Meets Spring -- Unitree Spring Festival Gala Robots Present "Cyber Real Kung Fu" in the Year of the Horse
[Picked up by 259 media titles]
2026-02-17 14:16